What is the Role of Immunotherapy for Patients with Advanced NSCLC and a Driver Mutation? episode artwork

EPISODE · Dec 18, 2015 · 20 MIN

What is the Role of Immunotherapy for Patients with Advanced NSCLC and a Driver Mutation?

from GRACEcast · host cancerGRACE Meetings

Dr. Greg Riely from Memorial Sloan-Kettering Cancer Center reviews the limited data that help clarify the probability of benefit from new immunotherapy agents among patients with advanced NSCLC and an identified driver mutation.

Episode metadata supplied by the publisher feed · Published Dec 18, 2015

Embed this episode

NOW PLAYING

What is the Role of Immunotherapy for Patients with Advanced NSCLC and a Driver Mutation?

0:00 20:05

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of GRACEcast?

This episode is 20 minutes long.

When was this GRACEcast episode published?

This episode was published on December 18, 2015.

Can I download this GRACEcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!